Resources to support you and your aHUS patients

ULTOMIRIS® OneSource™ Enrolment Form

Download

SOLIRIS® OneSource™ Enrolment Form

Download
ULTOMIRIS® Product Monograph SOLIRIS® Product Monograph
For any questions, feedback, or requests, please reach out to your local Alexion representative, or contact us online.
ULTOMIRIS®
Indications and Clinical Use:
ULTOMIRIS® (ravulizumab for injection) is indicated for:
  • The treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic hemolysis (TMA)

Limitations of Use: ULTOMIRIS® is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Contraindications:
  • Do not initiate ULTOMIRIS® in patients with unresolved Neisseria meningitidis infection

Most Serious Warnings and Precautions:
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Life-threatening meningococcal infections/sepsis have occurred in patients treated with ULTOMIRIS®. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.
  • Comply with the most current National Advisory Committee on Immunization (NACI) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Patients must be vaccinated against meningococcal infections prior to, or at the time of, initiating ULTOMIRIS®, unless the risks of delaying ULTOMIRIS® therapy outweigh the risks of developing a meningococcal infection.
  • Monitor patients for early signs of meningococcal infections and treat immediately if infection is suspected.
ULTOMIRIS® in Canada is available under a controlled distribution program. Patients are enrolled in a dedicated Patient Support Program (PSP).
For More Information:
Please consult the product monograph https://alexion.com/documents/ultomiris_product_monograph_approved_english for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling 1-844-922-0605.
SOLIRIS®
Indications and Clinical Use:
SOLIRIS® (eculizumab for injection) is indicated for:
  • The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to reduce complement-mediated thrombotic microangiopathy.
Limitations of Use: SOLIRIS® is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Contraindications:
Do not initiate SOLIRIS® in patients:
  • with unresolved Neisseria meningitidis infection
  • who are not currently vaccinated against Neisseria meningitidis (unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination)

Most Serious Warnings and Precautions:
SERIOUS WARNINGS AND PRECAUTIONS
Cases of serious or fatal meningococcal infections have been reported in patients treated with SOLIRIS®. Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.
  • Comply with the most current National Advisory Committee on Immunization (NACI) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • All patients must be vaccinated with meningococcal vaccines prior to, or at the time of, initiating SOLIRIS®, unless the risks of delaying SOLIRIS® therapy outweigh the risks of developing a meningococcal infection; revaccinate according to current medical guidelines for vaccine use.
  • All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.
Vaccination may not prevent all meningococcal infections.
For More Information:
Please consult the product monograph https://alexion.com/-/media/alexion_global/documents/regulatory/north-america/canada/2024/english/soliris_product_monograph_en_approved_24jul2024.pdf for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The product monograph is also available by calling 1-844-922-0605.